Stock THAR THARIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tharimmune, Inc.

Equities

THAR

US4327053090

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
5.11 USD -1.16% Intraday chart for Tharimmune, Inc. +13.81% -33.07%
May. 25 Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. CI
May. 25 Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tharimmune to Present at 2024 BIO International Convention
AQ
Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Tharimmune Announces 1-for-15 Reverse Stock Split
AQ
Tharimmune to Implement 1-for-15 Reverse Stock Split
MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates
AQ
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates
CI
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics
AQ
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
AQ
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104
CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease
MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients
CI
Sector Update: Health Care Stocks Retreat in Late Afternoon
MT
Top Midday Decliners
MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. THAR Stock
  4. News Tharimmune, Inc.